Active substance
Results for the substance etoposide
17 results
About this active substance
Etoposide is a chemotherapy drug used to treat various types of cancer, including small cell lung cancer, testicular cancer, lymphomas, and leukemias. It belongs to a class of drugs called topoisomerase II inhibitors, which work by interfering with cell division, thereby destroying rapidly dividing cancer cells.
The mechanism of action of etoposide involves inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. By blocking this enzyme, etoposide causes the accumulation of DNA strand breaks, leading to cancer cell death. It is administered either intravenously or orally, depending on the type of cancer and the treatment protocol.
While effective, etoposide can cause side effects. The most common include nausea, vomiting, loss of appetite, hair loss, fatigue, and a decrease in blood cell counts (myelosuppression), which can increase the risk of infections, bleeding, and anemia. In rare cases, severe allergic reactions or other complications, such as secondary leukemia, may occur, especially with long-term use.
Etoposide must be administered under the strict supervision of an oncologist, and patients should be regularly monitored to assess their response to treatment and detect potential side effects. It is contraindicated in patients with hypersensitivity to the active substance or severe bone marrow suppression. During treatment, it is important for patients to avoid contact with sick individuals and follow their doctor's recommendations to minimize associated risks.
The mechanism of action of etoposide involves inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. By blocking this enzyme, etoposide causes the accumulation of DNA strand breaks, leading to cancer cell death. It is administered either intravenously or orally, depending on the type of cancer and the treatment protocol.
While effective, etoposide can cause side effects. The most common include nausea, vomiting, loss of appetite, hair loss, fatigue, and a decrease in blood cell counts (myelosuppression), which can increase the risk of infections, bleeding, and anemia. In rare cases, severe allergic reactions or other complications, such as secondary leukemia, may occur, especially with long-term use.
Etoposide must be administered under the strict supervision of an oncologist, and patients should be regularly monitored to assess their response to treatment and detect potential side effects. It is contraindicated in patients with hypersensitivity to the active substance or severe bone marrow suppression. During treatment, it is important for patients to avoid contact with sick individuals and follow their doctor's recommendations to minimize associated risks.
-
-
VEPESID 100mg soft capsules CHEPLAPHARM ORIGINAL MEDICINE
-
ETOPOSIDE-TEVA 20mg/ml concentrate for solution for infusion
-
ETOPOZIDA KABI 20mg/ml concentrate for solution for infusion FRESENIUS
-
ETOPOSIDE-TEVA 20mg/ml concentrate for solution for infusion
-
SINTOPOZID 100mg/5ml concentrate for solution for infusion ACTAVIS
-
ETOPOSID ACCORD 20mg/ml concentrate for solution for infusion
-
ETOPOSID EBEWE 100mg/5ml concentrate for solution for infusion
-
ETOPOSID EBEWE200mg/10ml concentrate for solution for infusion
-
LASTET 100mg soft capsules ACTAVIS
-
LASTET 25mg soft capsules ACTAVIS
-
LASTET 50mg soft capsules ACTAVIS
-
ETOPOSID EBEWE 50mg/2.5ml concentrate for solution for infusion
-
ETOPOSID EBEWE 200mg/10ml concentrate for solution for infusion
-
ETOPOSIDE PIERRE FABRE 100mg/5ml 20mg/ml concentrate for solution for infusion
-
ETOPOSIDE 20mg/ml concentrate for solution for infusion PHARMACIA & UPJOHN P ORIGINAL MEDICINE
-
SINTOPOZID 100mg/5ml 20mg/ml concentrate for solution for infusion SINDAN